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Lipoprotein-X stimulates monocyte chemoattractant protein-1 Familial lecithin:cholesterol acyltransferase (LCAT)
expression in mesangial cells via nuclear factor-B. deficiency is a rare autosomal-recessive disorder [1]. Pa-
Background. Lipoprotein-X (Lp-X) is an abnormal lipopro- tients have little or no LCAT activity in their blood circula-
tein found in the plasma of patients with familial lecithin:cho-
tion because of mutations in the LCAT gene [2–4]. LCATlesterol acyltransferase (LCAT) deficiency. The majority of
is an enzyme that circulates in the blood primarily boundpatients with this disorder develop progressive glomeruloscle-
to high-density lipoprotein and catalyzes the formationrosis. One key event in the pathogenesis of glomerulosclerosis
is the infiltration of monocytes into affected glomeruli. Mesan- of cholesteryl esters via the hydrolysis and transfer of the
gial cells can synthesize and secrete monocyte chemoattractant sn-2 fatty acid from phosphatidylcholine to the 3-hydroxyl
protein-1 (MCP-1), an important chemoattractant for mono- group of cholesterol [1]. Patients with LCAT deficiency
cytes. The objective of the present study was to examine the have unusually high levels of phosphatidylcholine andeffect of Lp-X on MCP-1 expression in mesangial cells lead-
unesterified cholesterol, with corresponding low levelsing to an enhanced monocyte chemotaxis and to elucidate the
of lysophosphatidylcholine and cholesteryl ester in themechanisms involved in this process.
blood [1]. The lack of active LCAT, with the consequentMethods. Lp-X was isolated from the plasma of a patient
with familial LCAT deficiency. After rat mesangial cells were increase in both phospholipids and cholesterol as well
incubated with Lp-X for four or six hours, the expression of as a decrease in cholesteryl esters, leads to abnormalities
MCP-1 mRNA was determined by nuclease protection assay, in lipoprotein particle size and structure [5–7]. One strik-
and MCP-1 protein was measured by Western immunoblot-
ing feature of LCAT deficiency is the presence of anting analysis. Monocyte chemotaxis was determined by using
abnormal lipoprotein, lipoprotein-X (Lp-X), in patients’a Micro Chemotaxis Chamber.
plasma [1]. Lp-X is believed to arise from the surface ofResults. Lp-X (50 to 100 nmol/mL) stimulated mesangial
cell MCP-1 mRNA expression (137 to 220%) and MCP-1 pro- chylomicron remnants that are not further metabolized
tein levels (233 to 375%). Conditioned media collected from due to the absence of active LCAT [1, 8]. The Lp-X
Lp-X–treated mesangial cells stimulated human acute mono- particle is rich in phosphatidylcholine and unesterified
cytic leukemia (THP-1) monocyte chemotaxis (165 to 200%). cholesterol and is associated with a small amount of
The increase in MCP-1 expression in mesangial cells was associ-
proteins (apolipoprotein E, apolipoprotein CI, CII, andated with an elevation of intracellular diacylglycerol levels,
CIII, albumin) [8–11].and activation of protein kinase C (PKC) as well as nuclear
Clinical manifestations of LCAT deficiency typicallyfactor-B (NF-B).
Conclusion. These results suggest that Lp-X participates in include corneal opacities, hemolytic anemia, and protein-
the pathogenesis of glomerulosclerosis and subsequent renal uria leading to renal dysfunction [11–14]. A major com-
failure in familial LCAT deficient patients by stimulating mono- plication of LCAT deficiency is the development of pro-
cyte infiltration via a mechanism involving mesangial MCP-1
gressive glomerulosclerosis, which can lead to renal failureexpression.
[1, 3, 11–14]. Renal biopsies have revealed the presence
of foam cells in the glomerular tufts of affected glomeruli,
thickened intimas, and narrow lumens of renal arterioles,
Key words: familial LCAT deficiency, glomerulosclerosis, protein ki-
as well as the deposition of lipids in glomerular basementnase C, autosomal-recessive disorder, foam cells, unesterified choles-
terol, phosphatidylcholine. membrane and mesangial regions [15, 16]. These lipid
deposits in the kidney consist mostly of unesterified cho-Received for publication November 1, 2000
lesterol and phosphatidylcholine, the primary lipidsand in revised form February 19, 2001
Accepted for publication March 3, 2001 found in Lp-X [8–10]. We previously reported that the
direct deposition of Lp-X lipids and Lp-X–induced foam 2001 by the International Society of Nephrology
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cell formation might contribute to subsequent renal in-
jury in patients with LCAT deficiency [17, 18].
Several mechanisms by which lipoprotein abnormali-
ties lead to glomerulosclerosis have been proposed. These
include the deposition of lipids, proliferation of mesan-
gial cells, infiltration of monocytes/macrophages, and ac-
cumulation of extracellular matrix in glomeruli [11, 19–26].
The infiltration of monocytes/macrophages is one of the
key events in the development of glomerulosclerosis [11,
19–26]. Mesangial cells are able to synthesize and secrete
a variety of cytokines and growth factors, including
monocyte chemoattractant protein-1 (MCP-1), which is
a potent chemoattractant for monocytes/macrophages
Fig. 1. Lipoprotein electrophoresis. Samples were loaded on a 1%[27, 28]. Similar to the development of atherosclerosis,
agarose gel and electrophoresed for 35 minutes. The lipoproteins were
macrophage infiltration also plays an important role in stained with Sudan Black. The arrows indicate the position of individual
lipoproteins. Lane 1, normal plasma; lane 2, patient plasma; lane 3,glomerulosclerosis. Once infiltrated into arterial walls or
isolated Lp-X.organs monocytes differentiate into macrophages, which
can take up large amounts of lipoprotein-derived lipids
to form foam cells [18, 19, 24, 26]. Results from our
recent study suggest that very low-density lipoprotein centrifugation and column chromatography as previously
(VLDL)-induced MCP-1 expression in mesangial cells described [17, 34]. Briefly, a fraction with a density (d) of
occurred via a protein kinase C (PKC) signaling pathway 1.019 to 1.063 g/mL was prepared by sequential ultracen-
and may be responsible for increased macrophage infil- trifugation. The Lp-X present in the 1.019  d 
tration and foam cell formation in the kidney of patients 1.063 g/mL fraction was separated from low-density lipo-
with hypertriglyceridemia [29]. Furthermore, nuclear protein (LDL) by gel filtration column chromatography,
factor-B (NF-B), a transcription factor, also plays an using a matrix of Superose 6B beads (Amersham Phar-
important role in the up-regulation of MCP-1 expression macia Biotech, Uppsala, Sweden). Lp-X was eluted off
in many cell types [30–33]. the column as a distinct peak using a buffer of 0.15 mol/L
Although many mutations in the LCAT gene have NaCl/10 mmol/L Tris-HCl, pH 7.4. The peak was identi-
been identified, the mechanisms by which LCAT defi- fied by measuring absorbency at 280 nm. The purity of
ciency leads to glomerulosclerosis have not been fully
Lp-X was determined by the electrophoretic mobility of
elucidated. The presence of foam cells in the affected
the isolated Lp-X on 1% agarose gel (Fig. 1), as well
kidneys of patients with LCAT deficiency suggests that
as by the ratio (95%) of unesterified cholesterol:totalthe recruitment of monocytes/macrophages into glomer-
cholesterol [34]. Unesterified and total cholesterol in theuli is enhanced. The objective of the present study was
Lp-X fraction were measured enzymatically using com-to investigate the effect of Lp-X on MCP-1 expression
mercially available kits (Boehringer-Mannheim, Mann-leading to enhanced monocyte chemotaxis as well as the
heim, Germany). The concentrations of Lp-X used inunderlying mechanisms in this process.
the present study were comparable to those found in the
plasma of LCAT-deficient patients [35]. The concentra-
METHODS tion of Lp-X was expressed as nmol free cholesterol in
Lp-X per mL (nmol/mL). The protocol of the study wasPreparation of lipoprotein-X
approved by the university ethical review committee.Blood was obtained from a previously described pa-
tient of Italian and Swedish descent who was diagnosed
Cell culture
with familial LCAT deficiency after an overnight fast [12].
Mesangial cells were isolated from the glomeruli ofThe patient presented with symptoms similar to those
male Sprague-Dawley rats using a differential sieving tech-found in other reported cases of familial LCAT deficiency
nique as described previously [29, 36]. In brief, cortices[11, 13, 14]. The patient had a complete lack of active
were removed and minced before passage through aLCAT in the plasma, typical corneal opacities, mild ane-
series of steel sieves with decreasing pore sizes (200, 150,mia, and proteinuria [12]. Kidney biopsy revealed nu-
and 75 m). Isolated glomeruli were then digested withmerous vacuoles with lipid deposits [12]. Serum lipopro-
trypsin and collagenase. Mesangial cells were cultured intein electrophoresis on agarose gel showed the presence
RPMI-1640 medium containing 20% fetal bovine serumof the abnormal lipoprotein, Lp-X [12]. The plasma was
(FBS) supplemented with insulin (5 g/mL), transferrinprepared by low-speed centrifugation (1200 g, 20 min)
and stored at 70C until use. Lp-X was isolated by ultra- (5 g/mL), and selenium (95 ng/mL; Sigma Chemical Co.,
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St. Louis, MO, USA). The homogeneity of the culture product from the reverse transcription reaction. After
an initial denaturation for five minutes at 95C, 30 cycleswas verified by immunofluorescent staining and resistance
to the epithelial cytotoxin puromycin aminonucleoside, of PCR amplification (95C for 1 minute, 55C for 1
minute, and 72C for 2 minutes) were carried out fol-as previously described [36]. Cells were subcultured at
one- to two-week intervals. Cells between passages 6 lowed by an additional ten-minute extension at 72C. In
preliminary experiments, we found that 30 cycles of PCRto 12 were used for experiments. RPMI-1640 medium
containing 0.5% lipoprotein-depleted FBS was used for amplification provided optimum results. The PCR prod-
ucts were separated by 1.8% agarose gel (containingexperiments. Human acute monocytic leukemia (THP-1)
cells, a human monocyte cell line, were purchased from ethidium bromide) electrophoresis and were visualized
under ultraviolet light using a gel documentation systemthe American Type Culture Collection (ATCC, Rock-
ville, MD, USA). THP-1 cells were cultured in RPMI- (Bio-Rad Gel Doc1000). Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as an internal stan-1640 medium containing 10% FBS. There was no lipo-
polysaccharide (LPS) contamination in any of our re- dard to verify equal PCR product loading for each exper-
iment. After the RT-PCR reaction, the MCP-1 signalagents or Lp-X preparations as determined by the
E-TOXATE kit purchased from Sigma Chemical Co. was normalized by comparison with the GAPDH signal
from the same sample.
Determination of MCP-1 protein To confirm results obtained from RT-PCR, a nuclease
protection assay was performed using a kit according toAfter mesangial cells were incubated with Lp-X (25 to
100 nmol/mL), the amount of MCP-1 protein in the cul- the manufacturer’s instructions (Ambion Inc., Austin, TX,
USA). Briefly, total RNA (10 g) was hybridized withture medium was determined by solid-phase immuno-
assay [29]. Briefly, aliquots of culture media and purified [32P]-end-labeled MCP-1 oligonucleotide probe (Clon-
tech Laboratory Inc., Palo Alto, CA, USA) overnightMCP-1 protein (Calbiochem, La Jolla, CA, USA) were
applied to a nitrocellulose membrane (0.2 m) in a Bio- at 30C, followed by nuclease digestion to remove the
nonhybridized probe. After digestion, the protected frag-Dot SF microfiltration apparatus (Bio-Rad, Hercules,
CA, USA). The membrane was blocked with 2% non- ments were resolved on a denaturing 12% polyacryl-
amide gel containing 8 mol/L urea. A positive control,fat milk in phosphate-buffered saline (PBS) for two
hours and then probed with polyclonal anti–MCP-1 anti- 28S rRNA oligonucleotide probe (Ambion Inc.) was used
as an internal control. Bands corresponding to MCP-1bodies (Pepro Tech EC Ltd., London, UK). Blots were
developed using horseradish peroxidase-conjugated sec- mRNA and 28S rRNA were visualized using autoradiog-
raphy and analyzed using a gel documentation systemondary antibodies. Bands were visualized using enzyme
chemiluminescence (ECL) reagents (Amersham, Buck- (Bio-Rad Gel Doc1000). The ratio of MCP-1 to 28S
rRNA was calculated, and values were expressed as ainghamshire, UK) and analyzed with a gel documenta-
tion system (Bio-Rad Gel Doc1000 and Multi-Analyst percentage of control.
version 1.1).
Determination of chemotactic activity
Analysis of MCP-1 mRNA by reverse THP-1 monocyte chemotaxis was measured by using
transcription-polymerase chain reaction and a 48-well Micro Chemotaxis Chamber (Neuro Probe Inc.,
nuclease protection assay Gaithersburg, MD, USA) [37]. Mesangial cells were in-
cubated for six hours in the presence or absence of vari-Total RNA from cultured cells was isolated with
TRIzol Reagent as described by the manufacturer (Life ous concentrations of Lp-X. After incubation, an aliquot
of the medium (defined as conditioned medium) wasTechnologies, Gaithersburg, MD, USA). Total RNA was
then used for reverse transcription-polymerase chain reac- transferred to the lower chamber of the Micro Chemo-
taxis Chamber. The lower and upper chambers weretion (RT-PCR). RT-PCR was performed with 1 g total
RNA in a total volume of 20 L [6 mmol/L MgCl2, 10 separated by a 5 m pore-size polycarbonate membrane
(Neuro Probe Inc., Gaithersburg, MD, USA). An aliquotmmol/L dithiothreitol (DTT), 10 ng/L poly dT, 1 U/L
M-MLV reverse transcriptase]. The nucleotide sequences of THP-1 monocyte suspension (2  106 cells/mL) was
added to the upper chamber, and the monocytes wereof the primers used in the PCR reactions were derived
from rat spleen cells [27, 29]. The MCP-1 sense primer allowed to transmigrate for two hours. After transmigra-
tion, the surface of the membrane facing the THP-1 cell(5-ATC ACC AGC AGC AGG TGT CCC AAA GAA
GCT-3) and antisense primer (5-AGA AGT GCT suspension was scraped and washed three times according
to the manufacturer’s instructions. The migrated cells,TGA GGT GGT TGT GGA AAA GAG-3) were syn-
thesized by Life Technologies. The reaction mixture for toward the conditioned medium, were fixed and then
stained with hematoxylin. The number of migrated mono-PCR contained 10 mmol/L Tris-HCl, 5 mmol/L MgCl2,
1 mmol/L dNTP, 0.4 mol/L 5 primer, 0.4 mol/L 3 cytes was determined under light microscopy. The results
are expressed as a percentage of control.primer, 2 U Taq DNA polymerase, and 2 L cDNA
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Chemotaxis assay was also performed with freshly iso- lowed by incubation with [32P] end-labeled oligonucle-
otide containing the consensus sequence for the NF-Blated human blood monocytes. Human monocytes were
isolated from peripheral blood collected from healthy binding site (Life Technologies). The reaction mixture
was separated in a nondenaturing 6% polyacrylamidevolunteers using the Ficoll-Paque density gradient cen-
trifugation procedure (Amersham Pharmacia Biotech). gel that was later exposed to x-ray film at 70C. A
supershift assay was also performed to identify the spe-Mononuclear cells were separated from platelets by four
washes at 300  g for 10 minutes. Finally, monocytes cific NF-B subunits in the complex. Specific antibodies
(2 g) against p50, p65, or normal rabbit IgG (Santawere added to a culture dish containing 10% FBS and
were allowed to adhere to the surface of the dish. After Cruz Biotechnology Inc., Santa Cruz, CA, USA) were
added to the nuclear proteins (3 g) prior to EMSA.incubation for 45 minutes, nonadherent lymphocytes
were removed from the culture dish. Adherent mono-
Determination of intracellular diacylglycerolcytes were recovered by incubating with PBS contain-
levels by gas-liquid chromatographying 10 mmol/L ethylenediaminetetraacetic acid (EDTA)
for five minutes. After washing in PBS, monocytes were Intracellular diacylglycerol levels were determined as
previously described [42]. Briefly, cells were incubatedresuspended in RPMI 1640 and were used for the chemo-
taxis assay. in the absence or presence of Lp-X (25 to 100 nmol/
mL) for 30 minutes. After incubation, cellular lipids were
Determination of protein kinase C activity extracted using chloroform:methanol extraction [43]. Di-
acylglycerol was separated from other lipids by thin layerCell extracts were prepared as described previously
[29]. All steps for the preparation of cell extracts were chromatography on silica gel 60 plates with the solvent
system of toluene:diethyl ether:ethanol:triethylamine (50:performed at 4C. Mesangial cells were harvested in PBS
and pelleted by centrifugation. Cells were sonicated in 40:2:1, vol/vol/vol/vol) [44]. Bands were visualized using
iodine vapor. Before extraction, 5 g 1,2-dipalmitoyl-sn-0.2 mL lysis buffer [50 mmol/L HEPES, pH 7.5, 0.2%
(wt/vol) Triton X-100, 1 mmol/L EDTA, 1 mmol/L eg- glycerol (C16:0) were added as an internal standard.
Diacylglycerol was extracted from the TLC plates usingtazic acid (EGTA), 1 mmol/L DTT, 85mol/L leupeptin,
2 mmol/L benzamidine, 0.4 mmol/L phenylmethylsulfo- chloroform:methanol extraction [43]. The chloroform
phase was evaporated to dryness and dissolved in 20 Lnyl fluoride] followed by centrifugation at 100,000  g
for 20 minutes (TLA 120.2; Beckman, Palo Alto, CA, ethyl acetate. This lipid extract (5 L) was injected into
gas-liquid chromatography, which was performed as de-USA) to obtain a detergent-soluble fraction (superna-
tant). A 5 L aliquot of this fraction was used to deter- scribed previously [42] using an HP-1 Hewlett-Packard
fused silica capillary column (5890 Series II Gas Chroma-mine PKC activity. The PKC activity toward a synthetic
peptide (Ac-FKKSFKL-NH2) was determined as de- tograph Hewlett-Packard 5971A). The oven tempera-
ture was set from 205C to 345C at a rate of 6C perscribed by Edwards and Newton [38]. The standard reac-
tion mixture contained 50 mol/L peptide substrate in minute, and the carrier gas was hydrogen (0.5 bar).
20 mmol/L HEPES (pH 7.5), 1 mmol/L DTT, 100mol/L
Determination of phosphatidylcholine-specific[	-32P]ATP (1500 cpm/pmol), 5 mmol/L MgCl2, and
phospholipase C activity0.5 mmol/L CaCl2, and sonicated dispersions of brain
phosphatidylserine (140 mol/L) and diacylglycerol (3.8 Phosphatidylcholine-specific phospholipase C activity
was performed as previously described [45]. Briefly, cellsmol/L). In other experiments, PKC activity was deter-
mined in the absence of calcium. After an eight-minute were incubated in the absence or presence of Lp-X (25 to
100 nmol/mL) for 30 minutes. After incubation, cellsincubation at 30C, the reaction was terminated by spot-
ting an aliquot of the reaction mixture onto Whatman were washed and collected in buffer (2 mmol/L HEPES,
154 mmol/L NaCl, 1 mmol/L EDTA, pH 7.4). The cellP81 ion-exchange chromatography paper, followed by
four washes with 0.4% (vol/vol) phosphoric acid and a suspension was sonicated for 30 seconds and then centri-
fuged at 180  g for 10 minutes at 4C. The supernatant95% ethanol rinse. Radioactivity (32P) incorporation into
the peptide substrate was determined by liquid scintilla- was then centrifuged at 100,000 g for 90 minutes at 4C.
After ultracentrifugation, the pellet was resuspended intion counting [29].
buffer. Membrane fractions were frozen at 70C until
Determination of nuclear factor-B/DNA use. The membrane fraction (50 g) was incubated with
binding activity 100 L reaction buffer (100 mmol/L HEPES, 100 mmol/L
sodium acetate, pH 7.5), 100 L L-
-dipalmitoyl-[2-pal-Nuclear factor-B/DNA binding activity was deter-
mined by electrophoretic mobility shift assay (EMSA) mitoyl-9,10-3H(N)]-phosphatidylcholine (10Ci/mL; NEN
Life Science Products, Inc., Boston, MA, USA), and[39, 40]. Nuclear protein was isolated as previously de-
scribed [41]. In brief, nuclear protein (10 g) was incu- 100 L 6 mmol/L CaCl2 for one hour at 37C. Reactions
were stopped by the addition of 1 mL chloroform/meth-bated with reaction buffer for 15 minutes at 25C, fol-
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anol (2:1, vol/vol) containing 36 mmol/L HCl. Lipids
were extracted using chloroform:methanol extraction
[43]. Phosphatidylcholine and diacylglycerol were sepa-
rated by thin layer chromatography as described pre-
viously in this article. Individual lipids were visualized
using iodine vapor. Radioactivity was determined by liq-
uid scintillation counting.
Statistical analysis
The Student t test was used for statistical analysis be-
tween two groups. The level of statistical significance
was set at P  0.05.
RESULTS
Effect of Lp-X on the production of MCP-1
protein by mesangial cells
To investigate the effect of Lp-X on MCP-1 protein
levels, mesangial cells were incubated with Lp-X at vari-
ous concentrations. After incubation, culture media were
collected and assayed for MCP-1 protein by Western
immunoblotting analysis. As shown in Figure 2A, Lp-X
at the concentration of 50 or 100 nmol/mL significantly
increased MCP-1 protein levels in media cultured with
mesangial cells (233 to 375% of control). Lp-X at low
concentration (25 nmol/mL) had no significant effect on
MCP-1 protein levels (108% of control). In time course
experiments, the maximum stimulatory effect was observed
in cells incubated with Lp-X for six hours (Fig. 2B).
Fig. 2. Effect of lipoprotein-X (Lp-X) on monocyte chemoattractant
Effect of Lp-X on the expression of MCP-1 protein-1 (MCP-1) produced by mesangial cells. (A) Mesangial cells
were incubated for six hours in the presence or absence of differentmRNA in mesangial cells
concentrations of Lp-X. Aliquots of culture media were taken, and
To determine whether an increase in MCP-1 protein MCP-1 protein was determined by Western immunoblotting analysis.
(B) Mesangial cells were incubated with 50 nmol/mL Lp-X for variouslevels was due to changes in the expression of MCP-1
time periods, and MCP-1 protein levels in cultured media were deter-mRNA, total RNA was isolated from mesangial cells.
mined. Control cells were incubated in the absence of Lp-X. Results are
Semiquantitative RT-PCR analysis and nuclease protec- expressed as mean  SD (error bar) from three separate experiments.
*P  0.05; **P  0.01 when compared with the control.tion assay were performed to determine the expression
of MCP-1 mRNA. Comparable results were obtained
with both RT-PCR analysis (Fig. 3A) and nuclease pro-
tection assay (Fig. 3B). Lp-X (50 or 100 nmol/mL) stimu- angial cells incubated with Lp-X (50 to 100 nmol/mL).
lated MCP-1 mRNA expression (137 to 220% of control) Next, to determine whether MCP-1 was the major chemo-
in mesangial cells (Fig. 3 A, B). In time course experi- attractant protein responsible for Lp-X–induced chemo-
ments, the levels of MCP-1 mRNA in Lp-X–treated mes- taxis, antibody blocking experiments with anti–MCP-1
angial cells reached a maximum after four hours of incu- antibody (0.5 g/mL) were performed. As shown in Fig-
bation (Fig. 3C). ure 4A, the anti–MCP-1 antibody completely abolished
the enhanced monocyte chemotaxis induced by the con-
Effect of Lp-X–induced MCP-1 expression ditioned medium, indicating that MCP-1 was the major
on monocyte chemotaxis chemoattractant protein produced by Lp-X–treated mes-
To examine the effect of Lp-X on monocyte chemo- angial cells. Similar experiments were performed with
taxis, mesangial cells were incubated with Lp-X for six freshly isolated human blood monocytes. As shown in
hours, and the culture medium was then collected (de- Figure 4B, there was a significant increase in monocyte
fined as conditioned medium) and used for chemotaxis chemotaxis toward conditioned medium collected from
assays. As shown in Figure 4A, there was a significant mesangial cells incubated with Lp-X (100 nmol/mL).
increase in THP-1 monocyte chemotaxis (165 to 200% of Such a stimulatory effect was abolished by anti–MCP-1
antibody (Fig. 4B).control) toward conditioned medium collected from mes-
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Fig. 4. Effect of Lp-X-induced MCP-1 expression on monocyte chemo-
taxis. Conditioned media were collected from mesangial cells preincu-
bated for six hours in the presence or absence of Lp-X. For some
experiments, 0.5 g/mL anti–MCP-1 antibody was added. The chemo-
tactic activity of THP-1 monocytes (A) or fresh monocytes isolated
from human blood (B) toward conditioned media was measured using
a 48-well Micro Chemotaxis Chamber. The number of monocytes was
counted under light microscopy. Control cells were incubated in the
absence of Lp-X. The results are shown as the mean  SD from four
independent experiments. *P  0.05 or **P  0.01 when compared
with the control.
Fig. 3. Effect of Lp-X on MCP-1 mRNA expression in mesangial cells. Effect of PKC inhibitors, calcium channel blocker,
Mesangial cells were incubated with different concentrations of Lp-X and NF-B inhibitors on Lp-X–induced MCP-1for four hours. (A) After incubation, MCP-1 mRNA was determined
mRNA expression and monocyte chemotaxisby RT-PCR analysis with GAPDH as an internal standard. The PCR-
amplified cDNA derived from MCP-1 or GAPDH were separated by To investigate the mechanisms by which Lp-X could1.8% agarose gel electrophoresis containing ethidium bromide and visu-
induce MCP-1 expression, mesangial cells were incu-alized under ultraviolet light using a gel documentation system. This is
a typical picture representative of five separate experiments. (B) The bated with Lp-X (100 nmol/mL) in the presence or ab-
expression of MCP-1 mRNA in mesangial cells was analyzed by nuclear sence of PKC inhibitors, calcium channel blockers, orprotection assay with 28S rRNA as an internal standard. Bands corre-
NF-B inhibitors. As shown in Figure 5A, both stauro-sponding to MCP-1 mRNA and 28S rRNA obtained from nuclear
protection assay were visualized under ultraviolet light using a gel sporine and Ro-32-0432 (bisindolylmaleimide XI, HCl;
documentation system. Values were expressed as the relative expression Alexis Corporation, Gru¨nberg, Germany), two separateof MCP-1 mRNA normalized to 28S rRNA levels. (C) Mesangial cells
inhibitors of PKC, completely abolished Lp-X–inducedwere incubated with 50 nmol/mL Lp-X for various time periods, and
MCP-1 mRNA expression was determined by nuclear protection assay. MCP-1 mRNA expression. On the other hand, an inhibi-
Control cells were incubated in the absence of Lp-X. Results are de- tor of cAMP-dependent protein kinase (PKI peptide,picted as the mean  SD from three separate experiments. **P  0.01
TTYADFIASGRRNAIHD) [46] did not affect the stim-when compared with the control.
ulatory effect of Lp-X on MCP-1 expression (Fig. 5A).
Diltiazem, a calcium channel blocker, also inhibited Lp-X–
induced MCP-1 expression (Fig. 5A). These results sug-
gested that Lp-X–induced MCP-1 expression might be
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Fig. 5. Effect of protein kinase inhibitors, cal-
cium channel blocker, nuclear factor-B/pro-
tein kinase C (NF-B/PKC) inhibitors, or acti-
nomycin D on Lp-X–induced MCP-1 mRNA
expression in mesangial cells as well as on
monocyte chemotaxis. (A) Mesangial cells
were incubated with 100 nmol/mL Lp-X for
four hours in the presence or absence of the
PKC inhibitors (staurosporine or Ro-32-0432),
a calcium channel blocker (diltiazem), NF-B
inhibitors (NAC or TLCK), actinomycin D,
or cAMP-dependent protein kinase (PKI pep-
tide). After incubation, MCP-1 mRNA was
determined and the ratio of MCP-1 mRNA
to 28S rRNA was calculated. (B) Mesangial
cells were incubated with 100 nmol/mL Lp-X
for six hours in the presence or absence of
the PKC inhibitor (Ro-32-0432) or the NF-B
inhibitors (NAC or TLCK). After incubation,
culture media were collected and used for the
monocyte chemotaxis assay. Control cells were
incubated in the absence of Lp-X. Results are
depicted as the mean  SD from three inde-
pendent experiments. ** P  0.01 when com-
pared with the control.
mediated via PKC signaling pathway, while the cyclic preincubated with Lp-X significantly enhanced mono-
cyte chemotactic activity. Such a stimulatory effect wasadenosine monophosphate (cAMP)-dependent protein
kinase signaling pathway might not be involved in such completely abolished when mesangial cells were incu-
bated with Lp-X in the presence of PKC inhibitors orprocess in rat mesangial cells. Furthermore, N-acetylcys-
teine (NAC) or N-
-tosyl-L-lysine chloromethylketone NF-B inhibitors (Fig. 5B). These results suggested that
the activation of PKC and NF-B might be involved in(TLCK), both inhibitors of NF-B, blocked Lp-X–
induced MCP-1 mRNA expression (Fig. 5A), indicating Lp-X–induced MCP-1 expression in mesangial cells.
As a comparison, the effects of LPS on MCP-1 expres-that NF-B activation might be involved in mediating
this process. In addition, Lp-X–induced MCP-1 expres- sion and monocyte chemotaxis were investigated. LPS
is known to stimulate MCP-1 expression in various cellsion was completely inhibited by actinomycin D (Fig.
5A), indicating that Lp-X–induced MCP-1 expression types [47, 48]. LPS (10 g/mL; Sigma, Chemical Co.)
significantly stimulated the expression of MCP-1 mRNAwas at the transcription level. As shown in Figure 5B,
the conditioned medium collected from mesangial cells (Fig. 6A) and protein (Fig. 6B). The conditioned medium
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Fig. 7. Effect of Lp-X on PKC activity. Mesangial cells were incubated
with Lp-X (100 nmol/mL) for four hours in the absence or presence
of Ro-32-0432 (100 nmol/L). After incubation, PKC activities were
determined in the absence ( ) or presence () of calcium. Results
are depicted as the mean  SD from three independent experiments.
*P  0.05 when compared with the control.
ished by addition of anti–MCP-1 antibody. The effects
of Lp-X at the concentration of 100 nmol/mL on the
expression of MCP-1 mRNA, MCP-1 protein levels as
well as on monocyte chemotaxis were similar to that of
LPS at the concentration of 10 g/mL.
Effect of Lp-X on PKC activity and
NF-B activation
To determine the effect of Lp-X on PKC activity,
mesangial cells were incubated for four hours in the
absence or presence of Lp-X (100 nmol/mL). After incu-
bation, cell extracts were prepared, and PKC activity
was determined in the presence or absence of calcium.
Fig. 6. Effect of lipopolysaccharide (LPS) on monocyte chemoattrac-
As shown in Figure 7, Lp-X significantly stimulated thetant protein-1 (MCP-1) expression and monocyte chemotaxis. (A) Mes-
angial cells were incubated with LPS (10 g/mL) for four hours. After calcium-dependent PKC activity but had no effect on
incubation, MCP-1 mRNA was determined and the ratio of MCP-1 the calcium-independent PKC activity. Such effect was
mRNA to 28S rRNA was calculated. (B) Mesangial cells were incubated
abolished in the presence of a specific PKC inhibitor,for six hours with LPS (10g/mL), and MCP-1 protein levels in cultured
media were determined. (C) Conditioned media were collected from Ro-32-0432. These results indicated that Lp-X treatment
mesangial cells preincubated for six hours in the presence or absence increased PKC activity in mesangial cells. Next, to deter-
of LPS (10 g/mL). For some experiments, 0.5 g/mL anti–MCP-1
mine the effect of Lp-X on NF-B activation in mesan-antibody was added. The chemotactic activity of THP-1 monocyte to-
ward conditioned media was measured using a 48-well Micro Chemo- gial cells, EMSA was performed using a specific oligonu-
taxis Chamber. The number of monocytes was counted under light cleotide probe containing a NF-B/DNA binding site.
microscopy. Control cells were incubated in the absence of LPS. The
An increase in NF-B/DNA binding activity was ob-results are shown as the mean SD from four independent experiments.
**P  0.01 when compared with the control. served in mesangial cells treated with Lp-X (100 nmol/mL;
Fig. 8A). This stimulatory effect was abolished by the
addition of NF-B inhibitor (Fig. 8A). To determine
which NF-B subunits were activated, a supershift assay
collected from mesangial cells preincubated with LPS using antibodies against individual NF-B subunits was
significantly enhanced monocyte chemotactic activity performed. As shown in Figure 8B, the addition of either
p50 or p60 antibodies resulted in supershifts, indicating(Fig. 6C). Such stimulatory effect was completely abol-
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that these subunits were activated in Lp-X–treated cells.
Nonspecific IgG did not result in any shift of the NF-
B/DNA band (Fig. 8B). These results suggested that
Lp-X–induced MCP-1 expression might be mediated by
NF-B activation in mesangial cells. Next, the effect of
a PKC inhibitor (Ro-32-0432) on Lp-X–induced NF-B
activation was examined. As shown in Figure 8C, the
presence of Ro-32-0432 (100 nmol/L) in the culture me-
dium blocked Lp-X–induced NF-B activation in mesan-
gial cells.
Effect of Lp-X on intracellular diacylglycerol
levels and phosphatidylcholine-specific
phospholipase C activity
Lipoprotein-X is a lipid bilayer particle enriched with
phosphatidylcholine and unesterified cholesterol [1, 8–10].
To examine whether Lp-X could modulate effectors up-
stream of PKC (that is, diacylglycerol), mesangial cells
were incubated in the absence or presence of Lp-X for
30 minutes. After incubation, intracellular diacylglycerol
level and phosphatidylcholine-specific phospholipase C
activity were determined. Lp-X (25 to 100 nmol/mL) sig-
nificantly increased intracellular diacylglycerol levels
(123 to 158% of control; Fig. 9A). Elevated diacylglyc-
erol levels were accompanied by a significant increase (169
to 315% of control) in phospholipase activity (Fig. 9B)
following treatment with Lp-X (25 to 100 nmol/mL).
DISCUSSION
Similar to atherosclerosis, the findings that macro-
phages and foam cells accumulate in affected glomeruli
suggest that the recruitment of monocytes is increased
in glomerulosclerosis [13–17,19–22, 37, 49–51]. An in-
creased expression of MCP-1 mRNA has been detected
in kidneys of patients with several types of renal diseases
[47, 52–56]. However, the involvement of MCP-1 in fa-
milial LCAT deficiency has yet to be investigated. The
novel findings of the present study are as follows: (1)
Lp-X–stimulated MCP-1 expression in mesangial cells
leading to an enhanced monocyte chemotaxis; (2) that
stimulatory effect was abolished by inhibitors of PKC
or NF-B; and (3) Lp-X increased the activity of phos-

Fig. 8. Effect of Lp-X on NF-B/DNA binding activity. (A) Mesangial
cells were incubated with Lp-X (100 nmol/mL) for four hours in the
absence or presence of NF-B inhibitor (10 mmol/L NAC). EMSA was
performed to determine the NF-B/DNA binding activity. (B) Supershift
assay was performed in the presence of antibodies against p50, p65, or
nonspecific rabbit IgG. Antibodies against p50 or p65 caused a shift of
the NF-B/DNA band. (C ) Mesangial cells were incubated with Lp-X
(100 nmol/mL) for four hours in the absence or presence of a specific
PKC inhibitor (Ro-32-0432, 100 nmol/L). EMSA was performed to
determine the NF-B/DNA binding activity. The autoradiograph is a
representative EMSA from three separate experiments.
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gial cells [29, 51]. Calphostin C, a PKC inhibitor, was
also shown to inhibit the stretch-induced elevation of
MCP-1 mRNA levels in human endothelial cells [57]. In
our study, Lp-X significantly stimulated PKC activity in
mesangial cells. Furthermore, the PKC inhibitors stauro-
sporine and Ro-32-0432 completely abolished Lp-X–
induced MCP-1 expression. Taken together, these results
indicate that Lp-X–induced MCP-1 expression in mesan-
gial cells is mediated via the PKC signaling pathway.
Analyses of the promoter region of the MCP-1 gene
have revealed several putative binding sites for transcrip-
tion activator factors, including NF-B [30–33]. The acti-
vated NF-B can bind to the promoter region of the
MCP-1 gene and stimulate the expression of this chemo-
attractant protein [30–33]. In the present study, several
lines of evidence point toward a role for NF-B in MCP-1
expression. First, the NF-B inhibitors NAC and TLCK
completely blocked Lp-X–induced stimulation of MCP-1
mRNA levels and subsequent monocyte chemotaxis.
Second, the NF-B/DNA binding activity was signifi-
cantly elevated in Lp-X–treated cells. Third, a PKC in-
hibitor (Ro-32-0432) abolished Lp-X–stimulated NF-B
activation in mesangial cells. Moreover, Lp-X–induced
stimulation of MCP-1 expression appeared to occur at
the transcriptional level, as evidenced by the inhibitory
effect of actinomycin D. These results suggest that Lp-X–
induced PKC activity and subsequent NF-B activation
Fig. 9. Effect of Lp-X on intracellular diacylglycerol levels and phos- can stimulate the transcription of MCP-1.
phatidylcholine-specific phospholipase C activity in mesangial cells. The effect of Lp-X on diacylglycerol levels was also
Mesangial cells were incubated in the absence or presence of Lp-X (25
investigated. Diacylglycerol is formed via the action ofto 100 nmol/mL) for 30 minutes. (A) After incubation, cellular lipids
were extracted, and diacylglycerol (DAG) was measured by gas-liquid phospholipase C on either phosphatidylinositol or phos-
chromatography. (B) The membrane fraction of cells was used for the phatidylcholine [45, 58]. Because Lp-X contains a highdetermination of phosphatidylcholine-specific phospholipase C activity
level of phosphatidylcholine [8–10], it is plausible that(PC-PLC). Control cells were incubated in the absence of Lp-X. Results
are depicted as the mean  SD from three separate experiments. treatment of cells with Lp-X may stimulate phosphatidyl-
*P  0.05 when compared with the control. choline-specific phospholipase C activity to produce di-
acylglycerol, which in turn activates PKC. We previously
reported that mesangial cells were able to accumulate
phosphatidylcholine and lysophosphatidylcholine whenphatidylcholine-specific phospholipase C, causing an ele-
Lp-X was added to the culture medium [36]. In the pres-vation in the level of diacylglycerol in mesangial cells.
ent study, Lp-X treatment increased phosphatidylcho-In view that the stimulation of monocyte chemotaxis was
line-specific phospholipase C activity and intracellularcompletely abolished by anti–MCP-1 antibodies, Lp-X–
diacylglycerol levels in mesangial cells. While Lp-X atinduced MCP-1 might be the major chemoattractant pro-
the concentration of 25 nmol/mL elicited a significanttein responsible for enhanced monocyte chemotaxis in
response in both phospholipase C activity and diacylglyc-LCAT-deficient patients. Such a stimulatory effect in
erol levels, Lp-X at this concentration had no significantmesangial cells might be mediated by NF-B activation.
effect on the expression of MCP-1 mRNA and proteinThe monocyte recruitment via MCP-1 expression may
levels. Such a discrepancy might be due to the require-be one of the important mechanisms contributing to the
ment of a threshold level of intracellular calcium beforedevelopment of glomerulosclerosis in patients with fa-
a significant effect on activation of calcium-dependentmilial LCAT deficiency.
PKC and subsequent MCP-1 expression was evoked byIn the present study, we investigated the possible mech-
Lp-X. The minimum amount of Lp-X required for activa-anisms by which Lp-X stimulated MCP-1 expression, and
tion of phospholipase C leading to an elevation in thehence monocyte chemotaxis, in mesangial cells. It has
levels of intracellular diacylglycerol, a well-establishedbeen shown that VLDL or glucose-induced MCP-1 ex-
pression was mediated by PKC in rat or human mesan- allosteric activator of PKC [59, 60], might be different
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Fig. 10. Proposed mechanism for Lp-X–
induced monocyte chemotaxis. Lp-X stimu-
lates phosphatidylcholine-specific phospho-
lipase C (PLC) activity in mesangial cells,
producing increased levels of diacylglycerol
(DAG) that consequently activate PKC. In-
creased PKC activity in turn stimulates the
binding of NF-B to the MCP-1 gene, which
subsequently leads to an increase in MCP-1
mRNA expression and protein secretion. In-
creased monocyte chemotaxis due to Lp-X–
induced MCP-1 secretion contributes to mono-
cyte infiltration, lipid accumulation, and foam
cell formation, which are key events in the
development of glomerulosclerosis.
from that required for elevation of intracellular calcium also elicit calcium influx leading to a rise in intracellular
calcium. Such an increase in calcium, in combinationfor the activation of PKC.
In addition to the infiltration of circulating monocytes with the elevation in diacylglycerol levels, can activate
calcium-dependent PKC. Increased PKC activity subse-into affected glomeruli, another major event in the path-
ogenesis of glomerulosclerosis is the accumulation of quently may activate NF-B, which in turn leads to an
elevation in the expression of MCP-1 mRNA and MCP-1lipids in the kidneys of patients with LCAT deficiency
[1, 8–10]. Unesterified cholesterol from Lp-X, once taken protein. In the kidney, high concentrations of MCP-1
would enhance monocyte chemotaxis and infiltrationup into the cell, was esterified to cholesteryl ester by
mesangial cells [36]. We have reported previously that from the circulation into affected glomeruli. Infiltrated
macrophages as well as mesangial cells can continue toLp-X caused the direct deposition of lipids in perfused
rat kidney and induced foam cell formation in rat perito- take up excess lipids, ultimately forming foam cells.
Monocyte infiltration into affected glomeruli, the pres-neal macrophages [17, 18]. Hence, Lp-X may contribute
to the progression of glomerulosclerosis in familial ence of foam cells, and the deposition of lipids are all
key events in the development of glomerulosclerosis.LCAT deficiency by first stimulating lipid accumulation
in the kidney [19], followed by Lp-X–induced monocyte In conclusion, the present study has clearly demon-
strated that Lp-X, at pathophysiological concentrations,infiltration into affected glomeruli via a mechanism in-
volving MCP-1 expression. Once having been recruited stimulates monocyte chemotaxis via a mechanism involv-
ing MCP-1 expression in mesangial cells. Lp-X–inducedinto the kidney, these infiltrated monocytes/macrophages
could take up excessive lipoprotein lipids and become activation of PKC may mediate this effect by activation
of NF-B. These findings add to our understanding offoam cells [18, 24, 26]. In turn, these foam cells may then
secrete a wide variety of cytokines and growth factors the mechanisms by which patients with familial LCAT
deficiency develop glomerulosclerosis.that could exacerbate and further contribute to the
pathogenesis of glomerulosclerosis [50].
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